207 related articles for article (PubMed ID: 9563549)
1. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M
Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
[TBL] [Abstract][Full Text] [Related]
2. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
Nagler A; Genina O; Lavelin I; Ohana M; Pines M
Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128
[TBL] [Abstract][Full Text] [Related]
3. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M
J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768
[TBL] [Abstract][Full Text] [Related]
4. Halofuginone: a novel antifibrotic therapy.
Pines M; Nagler A
Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159
[TBL] [Abstract][Full Text] [Related]
5. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
Pines M; Knopov V; Genina O; Lavelin I; Nagler A
J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
[TBL] [Abstract][Full Text] [Related]
6. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A
Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455
[TBL] [Abstract][Full Text] [Related]
7. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery.
Nyska M; Nyska A; Rivlin E; Porat S; Pines M; Shoshan S; Nagler A
Connect Tissue Res; 1996; 34(2):97-103. PubMed ID: 8909874
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
Bruck R; Genina O; Aeed H; Alexiev R; Nagler A; Avni Y; Pines M
Hepatology; 2001 Feb; 33(2):379-86. PubMed ID: 11172339
[TBL] [Abstract][Full Text] [Related]
9. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
Nagler A; Pines M
Transplantation; 1999 Dec; 68(11):1806-9. PubMed ID: 10609960
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Abramovitch R; Dafni H; Neeman M; Nagler A; Pines M
Neoplasia; 1999 Oct; 1(4):321-9. PubMed ID: 10935487
[TBL] [Abstract][Full Text] [Related]
11. Halofuginone- and chitosan-coated amnion membranes demonstrate improved abdominal adhesion prevention.
Washburn S; Jennell JL; Hodges SJ
ScientificWorldJournal; 2010 Dec; 10():2362-6. PubMed ID: 21170487
[TBL] [Abstract][Full Text] [Related]
12. Halofuginone infused keratin hydrogel attenuates adhesions in a rodent cecal abrasion model.
Peyton CC; Keys T; Tomblyn S; Burmeister D; Beumer JH; Holleran JL; Sirintrapun J; Washburn S; Hodges SJ
J Surg Res; 2012 Dec; 178(2):545-52. PubMed ID: 22901798
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of prostate cancer xenografts by halofuginone.
Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone prevents subglottic stenosis in a canine model.
Eliashar R; Ochana M; Maly B; Pines M; Sichel JY; Nagler A
Ann Otol Rhinol Laryngol; 2006 May; 115(5):382-6. PubMed ID: 16739671
[TBL] [Abstract][Full Text] [Related]
15. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
Pines M; Snyder D; Yarkoni S; Nagler A
Biol Blood Marrow Transplant; 2003 Jul; 9(7):417-25. PubMed ID: 12869955
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M
Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725
[TBL] [Abstract][Full Text] [Related]
17. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes.
Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Abu-Amara SN; Geiger B; Genina O; Monsonego-Ornan E; Pines M
J Hepatol; 2004 Feb; 40(2):269-77. PubMed ID: 14739098
[TBL] [Abstract][Full Text] [Related]
18. Halofuginone, a specific inhibitor of collagen type 1 synthesis, ameliorates oxidant colonic damage in rats with experimental colitis.
Karakoyun B; Yüksel M; Ercan F; Salva E; Işik I; Yeğen BC
Dig Dis Sci; 2010 Mar; 55(3):607-16. PubMed ID: 19390970
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
20. Halofuginone: an inhibitor of collagen type I synthesis.
Granot I; Halevy O; Hurwitz S; Pines M
Biochim Biophys Acta; 1993 Feb; 1156(2):107-12. PubMed ID: 8427869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
